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Asthma is a condition of chronic airway inflammation, associated with hyperreactivity of the airways, lead-ing to recurrent episodes of breathlessness, wheezing, 
chest tightness, and coughing, particularly at night or in the 
early morning.1 It is a chronic disease that is prevalent world-
wide and affects approximately 300 million people of all ages, 
including 17.7 million American adults.2,3 Allergic rhinitis (AR) 
is the most common form of noninfectious rhinitis and is one of 
the most prevalent diseases of the airways.4,5 It is characterized 
by rhinorrhea, sneezing, nasal pruritus, and/or nasal obstruc-
tion.6,7 It is frequently undertreated and underdiagnosed and 
consequently uncontrolled.4 Patients suffering from AR often 
adapt to symptoms or self-medicate to relieve symptoms.6,8 
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ABSTRACT
BACKGROUND: Allergic rhinitis and asthma (ARA) are frequent respiratory 
diseases that often coexist, causing a high social and economic impact. It 
is important to maintain ARA disease control to reduce the disease burden.
OBJECTIVE: To assess control in patients with 1 or both pathologies through 
the application of validated questionnaires at community pharmacies.
METHODS: A cross-sectional study was conducted in the pharmacies of the 
Portuguese county of Covilhã (located in the central region of Portugal with 
about 53,000 inhabitants). Subjects aged between 18 and 70 years who 
presented a prescription for an asthma and/or allergic rhinitis medication 
were invited to participate in the study by responding to a questionnaire 
that included the Control of Allergic Rhinitis and Asthma Test (CARAT). The 
CARAT is a validated tool to simultaneously assess the control of ARA with 
scores that range from 0 to 30 points, 0 meaning the worst and 30 meaning 
the best possible control of disease.
RESULTS: Of the 224 participants, 58% were female and the median age 
was 48.5 years. The median CARAT score was 19 (mean = 17.8 ± 5136.4), and 
87% of participants had a score < 25, indicating noncontrolled disease. 
Female participants, the elderly, and those with less school education 
responded with scores that demonstrated significantly less disease control.
CONCLUSIONS: Using a simple self-assessment questionnaire, such as the 
CARAT, pharmacists can help identify patients with uncontrolled ARA dis-
ease, which is an important first step to change patients’ knowledge about 
their disease, with an ultimate goal of improving ARA outcomes.
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RESEARCH
•	Allergic	rhinitis	and	asthma	(ARA)	are	common	respiratory	dis-
eases that are strongly linked. More than 80% of asthma patients 
have allergic rhinitis (AR), and up to 40% of patients with AR 
have asthma.
•	Epidemiological,	clinical,	and	pathological	studies	suggest	that	the	
upper and lower airways provide for “a continuum of a disease.”
•	According	to	the	guidelines	of	 the	Global	Initiative	for	Asthma,	
the goal of asthma therapy is to achieve overall control for 
extended periods.
•	When	 asthma	 is	 under	 control,	 there	 should	 be	 no	more	 than	
occasional	symptoms,	and	exacerbations	should	be	rare.	Effective	
treatment exists, and ARA education and pharmaceutical inter-
ventions can improve control of both respiratory diseases.
What is already known about this subject
•	Several	 standardized	measures	 to	 assess	 the	 clinical	 control	 of	
asthma have been developed, and methods to assess control of 
AR in the community are now being introduced. The Control 
of Allergic Rhinitis and Asthma Test (CARAT) is a tool that was 
developed and validated to simultaneously assess the control of 
both diseases of the upper and lower airways.
•	AR	is	a	disease	with	high	prevalence,	often	underdiagnosed	and	
undertreated, and few studies have been conducted to analyze its 
control in a community setting. This study is the first conducted 
in a community pharmacy setting that assessed AR and asthma 
control simultaneously.
•	Results	 show	 that	 AR	 control	 is	 as	 low	 as	 control	 for	 asthma.	
Almost half of the study cohort was only diagnosed with AR, but 
in this group, the control of AR was only slightly better than the 
control in patients with asthma and AR.
•	In	patients	diagnosed	only	with	AR,	about	50%	had	a	score	cor-
responding to poor asthma control, which may mean a lack of an 
asthma diagnosis in some cases.
•	The	 sharp	 contrast	 between	 perception	 of	 disease	 control	 and	
actual control suggests that administering the CARAT while the 
patient is at the pharmacy may be an opportunity to increase 
patient awareness of poor control.
•	The	 community	 pharmacist	 plays	 an	 important	 role	 for	 ARA	
control, providing information about medications, including 
frequency of administration, minimalization of side effects, and 
correct use of the inhaler devices.
What this study adds
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developed and validated to simultaneously assess control of 
diseases of the upper and lower airways.18-20
The CARAT has been used in clinical practice but has not 
been studied in a community pharmacy setting. There are few 
studies that analyze the role of pharmacists for detecting level 
of ARA control. The existing studies conducted in pharmacies 
mainly assess the control level of asthma and, in general, poor 
asthma control.21-23 Identifying patients with poor ARA control 
may be the first step to helping patients obtain adequate treat-
ment and to optimizing disease control.
This study assessed ARA control in patients with asthma, 
with AR, and with ARA at community pharmacies, using the 
CARAT tool for assessment.
■■  Methods
Study Design and Participants
This was a cross-sectional study conducted at pharmacies in 
Covilhã, a county of 53,000 inhabitants in the interior cen-
tral region of Portugal. All pharmacies in the county were 
contacted and invited to participate; 15 of the 18 pharmacies 
agreed to collaborate in the study.
Patients aged between 18 and 70 years with a refill prescrip-
tion for AR and/or asthma-specific medication were included. 
Patients who were not able to understand or participate in the 
study	 were	 excluded	 (Figure	 1).	 Exclusion	 criteria	 included	
refusal to participate in the study, illiteracy, presenting pre-
scriptions for other people, and aged < 18 or > 70 years.
This study was approved by the ethics committee of the 
Faculty	of	Health	Sciences	of	 the	University	of	Beira	 Interior.	
All participants signed a written informed consent form. 
Information in the questionnaires was kept anonymous.
Data Collection
Data were collected between December 2011 and May 2012, 
using an anonymous self-report questionnaire. Pharmacy per-
sonnel (i.e., pharmacists and pharmacy technicians) assisted 
In	Western	Europe,	including	Portugal,	the	overall	prevalence	
of clinically confirmed AR is about 23%-26%.6	 In	 the	United	
States,	 an	estimated	50	million	Americans,	 about	16%	of	 the	
population, are thought to be affected by AR.9
Data suggest that the upper and lower airways can be 
thought of as “a continuum of a disease.”10	 Epidemiological,	
clinical, and pathological studies establish a strong link 
between asthma and allergic rhinitis, and they often occur 
together, as more than 80% of asthma patients have AR, and 
up to 40% of patients with AR have asthma.5 The presence of 
AR in asthmatics increases the risk of asthma exacerbations, 
hospitalizations, and emergency room visits.11 Moreover, the 
greater the severity of AR, the worse the asthma control.12 
Allergic rhinitis and asthma (ARA) are an important cause 
of disability, carrying a high social and economic impact on 
patients, families, and health care systems.4 For asthma in par-
ticular, patients with severe and uncontrolled disease account 
for the use of more health resources and a much larger share of 
health costs than patients with controlled disease.3
The	Global	 Initiative	 for	 Asthma	 guidelines	 state	 that	 the	
goals of asthma therapy are to achieve overall control for 
extended periods in order to minimize the impact of the dis-
ease, decrease the medical costs related to asthma therapy and 
hospital services, and reduce the potential for adverse effects.5 
When	asthma	is	under	control,	there	should	be	no	more	than	
occasional symptoms, and exacerbations should be rare.1 
Nevertheless, many asthmatics have relatively low expecta-
tions of their medication clinical outcomes and accept a lower 
level of control than what could be achieved by optimizing 
therapy.13-15
Several	 standardized	 measures	 to	 assess	 the	 clinical	 con-
trol of asthma have been developed. One of the validated 
instruments is the Asthma Control Test (ACT).16 Methods to 
assess control of AR are also being introduced.5,17 Recently, 
the Control of Allergic Rhinitis and Asthma Test (CARAT) was 
FIGURE 1 Participants Flowcharta
aAfter excluding refusals and cases not meeting inclusion criteria, this study had 224 participants (asthma and rhinitis subgroup, n = 120; allergic rhinitis only subgroup, n = 104).
Patients with asthma 
and/or allergic rhinitis
(n = 333)
Refusals (n = 27)
Inclusion criteria not met (n = 82)
  Illiteracy (n = 3)
  < 18 years (n = 18)
  > 70 years (n = 29)
  Prescription for other people  (n = 32)
Participants with medical 
prescription in its own name
(n = 224)
Prescription for asthma 
medication only
(n = 120)
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in completing the questionnaire when necessary, for example, 
when the patient did not understand some of the terms used 
or had difficulty perceiving the scales. The level of asthma and 
allergic rhinitis control was assessed by the validated question-
naire	CARAT	and	by	a	Visual	Analogue	Scale	(VAS).19 Asthma 
control was also assessed by the ACT.24 Additional collected 
data included age, gender, smoking habits, and family history 
of allergic disease.
Participants were grouped according to the prescribed med-
ication (for medication used in this study, see the Appendix). 
Those participants with an asthma-specific medication and 
an AR-specific medication were included in the “asthma and 
rhinitis” group, and those with an AR-specific medication but 
without an asthma medication were included in the “AR only” 
group. The ACT questionnaire was completed only by patients 
in the AR group.
CARAT has 10 questions that ask about symptomatology 
during the previous 4 weeks (Table 1). CARAT total score 
(CARAT-t) ranges from 0 to 30, with a score higher than 24 
indicating good overall control. The questionnaire is further 
divided into 2 sections: the first section relates to allergic rhini-
tis (CARAT-r), with a score range of 0 to 12 and a value higher 
than 8 identifying controlled AR; the second section relates to 
asthma (CARAT-a), with a score range of 0 to 18 and a value of 
16 or higher identifying controlled asthma.19,25
The	VAS	measures	 overall	 symptom	 severity,	 nasal	 symp-
toms, and bronchial symptoms, using a scale of 1 to 10, where 
a score of 1 means no symptoms or untroublesome symptoms, 
and a score of 10 indicates the worst possible or extremely 
troublesome symptoms. Patients who responded with answers 
from 1 to 6 were considered to have “controlled” symptoms, 
and those who answered within the range of 6 to 10 were clas-
sified as “not controlled.”26
Statistical Analysis
Data	 analysis	 was	 performed	 using	 the	 SPSS	 software	 pack-
age,	version	19.0	(SPSS	Inc.,	Chicago,	IL).	Categorical	variables	
were described by absolute (n) and relative (%) frequencies, 





were used, when appropriate. The chi-square test analyzed 
associations between categorical variables, and the association 
between scores of the different questionnaires was carried out 
using	the	Pearson’s	or	Spearman’s	correlation	coefficient.
Statistically	significant	differences	between	2	variables	were	




and 224 were included and completed the questionnaires. Of 
the 82 patients who did not meet the inclusion criteria, 55 did 
not provide a prescription in their own name, and the remain-
ing were younger or older than the target population. Of the 
224 eligible patients, 120 had a prescription for a medication 
to treat asthma and therefore also filled in the ACT (Figure 1). 
Participants were aged between 18 and 70 years, with a median 
of 48.5 years. Of those with asthma and allergic rhinitis, the 
median age was 54.5 years, and the most frequent age group 
was 61-70 years (32%, Table 2). For the AR only group, the 
median age was 42.0 years. The gender distribution of the total 
sample showed a slight predominance of females (58%). About 
94% of the subjects lived in the county of Covilhã and were 
Never
Up to 2 Days  
Per Week
More Than 2 Days  
Per Week
Almost Every Day  
or Every Day
Questions A AR T A AR T A AR T A AR T
1.	Blocked	nose 14 13 13 34 38 36 27 29 28 25 21 23
2.	Sneezing 8 9 8 30 38 31 28 30 29 34 29 32
3. Itchy nose 21 24 22 30 38 31 23 26 25 26 18 22
4. Runny nose 23 14 18 32 40 36 21 23 22 25 23 24
5. Dyspnea 28 76 50 39 14 27 18 9 13 16 2 9
6.	Wheezing	in	the	chest 29 77 51 32 15 24 16 4 10 23 4 14
7. Chest tightness upon physical exercise 30 77 52 32 19 26 26 3 15 13 1 7
8.	Limitations	in	doing	daily	tasks 19 52 34 35 38 36 23 7 15 23 4 14
9.	Wake	up	during	the	night 18 40 28 30 31 30 29 20 25 23 9 17
Not Taking Medication Never Less Than 7 Days 7 or More Days
10. Medication use increase 13 33 22 23 25 24 42 32 37 23 11 17
aAll answers are given as a percentage. Cohort numbers: asthma and rhinitis (n = 120); allergic rhinitis only (n = 104); total sample (n = 224). Answers in grey were the most 
frequent response for each question.
A = asthma and rhinitis group; AR = allergic rhinitis only group; CARAT = Control of Allergic Rhinitis and Asthma Test; T = total sample.
TABLE 1 Subgroup Answers on CARAT Questionnairea
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evenly distributed between urban and rural areas (105 and 106 
inhabitants, respectively, Table 2).
Asthma and Allergic Rhinitis Control
Study	 results	 showed	 that	 the	 level	 of	 control	was	higher	 for	
males than for females, 18% versus 10% (P < 0.05, Table 3). 
The average CARAT-t was 19 for males and 17 for females 
(P = 0.005, data not shown). ARA control was higher for the 
younger age groups compared with the older age groups 
(P < 0.05, Table 3). For the age group 18-30, the median CARAT 
score was 21 points, and for the age group 61-70, the median 
was 15. The frequency of uncontrolled individuals, accord-
ing to CARAT-a, is markedly higher than the controlled in 
all age groups. However, control decreased with increasing 
age (P < 0.001, data not shown). In general, ARA control was 
greater with increased years of education (P < 0.05, Table 3). 
Regarding the CARAT-t, the median score was 20.5 for those 
who had studied more than 12 years, while for those who did 
not attend school the median score was 14.5. The control level 
was similar for those who had no family history of asthma 
when compared with those with at least 1 family member with 
asthma (14% vs. 13%, Table 3). However, the average CARAT-t 
score was significantly higher for those with no family history 
of asthma, 19 and 17, respectively (P = 0.015, data not shown). 
The CARAT questionnaire answers are summarized in Table 1. 
For the questions related to AR symptoms, the most frequent 
answer was “up to 2 days per week” regarding asthma symp-
toms; the option “never” was the most frequent in the allergic 
rhinitis symptoms questions. In the asthma and rhinitis group, 
almost 16% of participants claimed to have shortness of breath 
“almost every day or every day.” For the AR only group, 21% 
had blocked nose “almost every day or every day.”
The majority of individuals had uncontrolled disease 
(86.6%, Table 4 and Figure 2A). The median scores were 19, 
6, and 13 for CARAT-t, CARAT-r, and CARAT-a, respectively 
(data not shown). For participants who completed the ACT, 
only	about	25%	had	controlled	disease	(Figure	2B).	In	contrast,	
most patients had a perception of good disease control, with 
50.8% of the participants rating their asthma as “more or less 
controlled,” 28.3% as “well controlled,” and 10% as “completely 
controlled.” The median ACT score was 16 (mean = 16.6 ± 4.3). 




the frequencies of uncontrolled were much higher compared 
with controlled (Table 4). For the total sample, the nasal symp-
toms presented a smaller level of no control (66.1%, Table 4) 
than the bronchial symptoms (73.2%, Table 4). Compared with 
CARAT,	the	VAS	results	reflect	a	slightly	better	control	for	both	
upper and lower airways (Table 4).
Associations Between Control Measures
The	correlations	coefficients	between	CARAT-t,	ACT,	and	VAS	
are	 shown	 in	 Table	 5.	 The	 values	 between	CARAT	 and	 VAS	
are negative because good control on CARAT means poor 
control	on	VAS.	The	association	with	regard	to	ACT	was	made	
with CARAT-a because only these data are related to asthma 
control. There was a strong correlation between CARAT-a and 
ACT (r = 0.799). The correlations between CARAT-r and nasal 
symptoms	on	VAS	were	lower	(r	=	-0.485).
■■  Discussion
This study was the first conducted in a community pharmacy 










Male  94 (42.0)  52 (43.4)  42 (40.4)
Female  130 (58.0)  68 (56.7)  62 (59.6)
Age groups in years
18-30  46 (20.5)  17 (14.2)  29 (27.9)
31-40  37 (16.5)  18 (15.0)  19 (18.3)
41-50  35 (15.6)  15 (12.5)  20 (19.2)
51-60  56 (25.0)  32 (26.7)  24 (23.1)
61-70  50 (22.3)  38 (31.7)  12 (11.5)
Years of education
Did not attend school  8 (3.6)  6 (5.0)  2 (1.9)
< 4  21 (9.4)  19 (15.8)  2 (1.9)
4-9  58 (25.9)  35 (29.2)  23 (22.1)
9-12  51 (22.8)  28 (23.3)  23 (22.1)
> 12  86 (38.4)  32 (26.7)  54 (51.9)
Pharmacy type
Urban  117 (52.2)  62 (51.7)  55 (52.9)
Rural  107 (47.8)  58 (48.3)  49 (47.1)
Residence
Urban  105 (46.9)  56 (46.7)  49 (47.1)
Rural  106 (47.3)  60 (50.0)  46 (44.2)
Out of the county  13 (5.8)  4 (3.3)  9 (8.7)
Smoking habits
Smoker  28 (12.5)  13 (10.8)  15 (14.4)
Nonsmoker  155 (69.2)  80 (66.7)  75 (72.1)
Ex-smoker  41 (18.3)  27 (22.5)  14 (13.5)
Environmental smoke
None  165 (73.7)  85 (70.8)  80 (76.9)
At home  37 (16.5)  26 (21.7)  11 (10.6)
At work  15 (6.7)  7 (5.8)  8 (7.7)
Both  7 (3.1)  2 (1.7)  5 (4.8)
Family history of asthma  93 (41.5)  61 (50.8)  32 (30.8)
Family history of  
allergic rhinitis
 98 (43.8)  49 (40.8)  49 (47.1)
aParticipants in subgroups had a prescription for allergic rhinitis medication only 
(n = 104) or had a prescription for asthma and/or allergic rhinitis medication 
(n = 120). All answers are given as n (%).
TABLE 2 Participant Characteristicsa
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asthma control. ARA control is markedly low as measured by 
these study methods. In patients who experienced AR only, 
merely 16% of the sample reported symptom control, and in 
the participants treated for asthma and rhinitis, 14% reported 
disease control.
ARA control, and specifically asthma control, was lower in 
older participants. This finding is in agreement with previously 
reported results, where lower asthma control is associated with 
increasing age.12,22,27 There are several possible explanations, 
including concomitant chronic obstructive pulmonary disease 
(COPD), side effects of other medications, and complicated 
medication regimens that may inhibit or interfere with adher-
ence with all therapy regimens.22
According to the ACT, 75% of the patients had poorly con-
trolled asthma. This value was higher than that obtained in 
other Portuguese studies that used ACT. A different project, 
also carried out in a pharmacy environment, had 61.2% of the 
volunteers with an ACT score < 20,22 and a study that assessed 
patients treated at allergy departments in hospitals had 23.3% 
of the volunteers with an ACT score < 20.28 These differences 
may be related not only to regional and sociodemographic 
factors, but also to the health care setting, the hospital, or the 
community pharmacy.
The analysis of the question “how would you rate your 
asthma control during the past 4 weeks” showed that the 
majority of the participants had a poor perception of their level 
Total (n = 224) Asthma and Rhinitis (n = 120) Allergic Rhinitis Only (n = 104)
Controlled Not Controlled Controlled Not Controlled Controlled Not Controlled
Gender
Male  17 (18.1)b  77 (81.9)b  11 (21.2)b  41 (78.8)b  8 (19.0)  34 (81.0)
Female  13 (10.0)b  117 (90.0)b  6 (8.8)b  62 (91.2)b  7 (11.3)  55 (88.7)
Age groups in years
18-30  9 (19.6)b  37 (80.4)b  3 (17.6)  14 (82.4)  5 (17.2)  24 (82.8)
31-40  5 (13.5)b  32 (86.5)b  5 (27.8)  13 (72.2)  1 (5.3)  18 (94.7)
41-50  9 (25.7)b  26 (74.3)b  2 (13.3)  13 (86.7)  6 (30.0)  14 (70.0)
51-60  4 (7.1)b  52 (92.9)b  1 (3.1)  31 (96.9)  1 (4.2)  23 (95.8)
61-70  3 (6.0)b  47 (94.0)b  6 (15.8)  32 (84.2)  2 (16.7)  10 (83.3)
Years of education
Did not attend school  0 (0.0)b  8 (100.0)b  1 (16.7)b  5 (83.3)b  1 (50.0)  1 (50.0)
< 4  1 (4.8)b  20 (95.2)b  2 (10.5)b  17 (89.5)b  1 (50.0)  1 (50.0)
4-9  4 (6.9)b  54 (93.1)b  3 (8.6)b  32 (91.4)b  1 (4.3)  22 (95.7)
9-12  7 (13.7)b  44 (86.3)b  5 (17.9)b  23 (82.1)b  2 (8.7)  21 (91.3)
> 12  18 (20.9)b  68 (79.1)b  6 (18.8)b  26 (81.3)b  10 (18.5)  44 (81.5)
Pharmacy type
Urban  15 (12.8)  102 (87.2)  10 (16.1)  52 (86.9)  8 (14.5)  47 (85.5)
Rural  15 (14.0)  92 (86.0)  7 (12.1)  51 (87.9)  7 (14.3)  42 (86.7)
Residence
Urban  16 (15.2)  89 (84.8)  9 (16.1)  47 (83.9)  7 (14.3)  42 (86.7)
Rural  11 (10.4)  95 (89.6)  7 (11.7)  53 (88.3)  6 (13.0)  40 (87.0)
Out of the county  3 (23.1)  10 (76.9)  1 (25.0)  3 (75.0)  2 (22.2)  7 (77.3)
Smoking habits
Smoker  4 (14.3)  24 (85.7)  2 (15.4)  11 (84.6)  5 (33.3)  10 (66.7)
Nonsmoker  22 (14.2)  133 (85.8)  10 (12.5)  70 (87.5)  8 (10.7)  67 (89.3)
Ex-smoker  4 (9.8)  37 (90.2)  5 (18.5)  22 (81.5)  2 (14.3)  12 (85.7)
Environmental smoke
None  22 (13.3)  143 (86.7)  11 (12.9)  74 (87.1)  10 (12.5)  70 (87.5)
At home  4 (10.8)  33 (89.2)  4 (15.4)  22 (84.6)  2 (18.2)  9 (81.8)
At work  3 (20.0)  12 (80.0)  1 (14.3)  6 (85.7)  1 (12.5)  7 (87.5)
Both  1 (14.3)  6 (85.7)  1 (50.0)  1 (50.0)  2 (40.0)  3 (60.0)
Family history of asthma  12 (12.9)b  81 (87.1)b  4 (6.6)  57 (93.4)  7 (21.9)  25 (78.1)
Family history of allergic rhinitis  14 (14.3)  84 (85.7)  6 (12.2)  43 (87.8)  7 (14.3)  42 (85.7)
aControlled and uncontrolled disease compared. Disease is considered controlled if CARAT total score is higher than 24. All answers given as n (%). 
bP < 0.05.
CARAT = Control of Allergic Rhinitis and Asthma Test; CARAT-t = CARAT total score.
TABLE 3 Asthma Control According to CARAT-t Score by Sociodemographic Featuresa
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provide information about medication benefits, including fre-
quency of administration, methods to reduce side effects, and 
correct use of inhaler devices.22 In the majority of Portuguese 
pharmacies, a software is used that allows pharmacists to cre-
ate a file for each user and keep records of all prescribed medi-
cation, over-the-counter (OTC) drugs, and historical results of 
measurements conducted in the pharmacy. This same system 
can also be used to record the CARAT results by date. The 
score of the questionnaire can help the pharmacist to justify 
an OTC indication or the need for a medical consultation. 
Furthermore, in order to contribute to the dissemination of 
CARAT, a website and a smartphone application, mCARAT, 
have been developed. This application allows patients to fill out 
the questionnaire, sets alarms for tasks such as taking medica-
tions, and includes several features for recording symptoms, 
exacerbations, and scheduled or unscheduled medical visits.34 
The results can be shared via e-mail with other users and also 
with the physician.
It is important to recognize possible causes for the low 
degree of observed disease control. In addition to poor percep-
tion of asthma control, adults with poorly controlled disease 
may not be aware of the availability of effective anti-inflamma-
tory medication. Poor disease control may also be associated 
with low continuity of care related to a poor doctor-patient 
relationship, negative attitudes and concerns about the use of 
medication, overreliance on quick-relief bronchodilators, and 
little understanding of the disease, as there are more uncon-
trolled patients that are not aware of the causes underlying 
their pathology.29
Future studies should address reasons contributing to poor 
ARA control and evaluate the cost-effectiveness of community 
pharmacy-based assessment of ARA.
Limitations
This study has several limitations that could affect the gener-
alizability of the results. First, the number of participants in 
the study is insufficient to extrapolate the data to a national 
context.	 Second,	 since	 this	 study	 relied	 only	 on	 the	 patients	
who presented a prescription for an allergy and/or asthma 
of control, with only 11% of the asthmatics reporting their 
asthma as not controlled or poorly controlled. One possible 
explanation	 for	 the	 difference	 between	 patients’	 perception	
of control is that individuals who have poorly controlled dis-
ease adapt to frequently feeling poorly.29 The sharp contrast 
between perception of control and the status of control sug-
gests that filling out a CARAT while at their local pharmacy 
may be an opportunity for patients to increase their awareness 
of	poor	disease	control.	Using	a	simple	self-assessment	ques-
tionnaire, such as the CARAT, pharmacists can help identify 
patients with uncontrolled ARA disease, which is an important 
first	 step	 to	 change	 patients’	 knowledge	 about	 their	 disease,	
with an ultimate goal of improving ARA outcomes.
The results of this study, showing overall poor asthma con-
trol in a community population, are similar to those obtained 
in 3 other studies that recruited patients from a similar setting. 
One study conducted at 348 pharmacies in 9 French cities 
showed that patients with ARA have a low degree of control, 
as measured by a questionnaire, while the study volunteers 
reported that their asthma was well controlled or completely 
controlled.23 Another study, conducted via patient question-
naire at 54 pharmacies in Flanders, showed a high percentage 
of insufficiently controlled asthmatic patients, as assessed by 
patient responses and peak expiratory flow rate.21 A study 
carried out in Portugal evaluated the degree of asthma control 
with a self-reported diagnosis and concomitant asthma therapy 
using ACT. The authors found a high degree of uncontrolled 
asthma, especially in older patients and, in general, a blunted 
perception of disease control.22
In the pharmacy setting, following the assessment of ARA 
control, some additional interventions may be proposed. 
Adherence to treatment is a key factor,30 with increased compli-
ance associated with better disease control.27 Asthma education 
and pharmaceutical interventions can improve its control.14,15 
The	potential	benefits	of	a	pharmacist’s	contribution	to	asthma	
management have been previously reported.31-33	 Briefly,	 in	
Portugal, the health system is public and universal, but the 
pharmacies are private with guaranteed universal access. 
As such, the community pharmacy is in an optimal place to 
Total (n = 224) Asthma and Rhinitis (n = 120) Allergic Rhinitis Only (n = 104)
CARAT-t 194 (86.6) 108 (90.0) 86 (82.7)
CARAT-r 189 (84.4) 100 (83.3) 89 (85.6)
CARAT-a 161 (71.9) 103 (85.8) 58 (55.8)
VAS	all	symptoms 161 (71.9) 75 (62.5) 86 (82.7)
VAS	nasal	symptoms 148 (66.1) 81 (67.5) 78 (65.0)
VAS	bronchial	symptoms 164 (73.2) 67 (64.4) 86 (82.7)
aAll answers given as n (%).
CARAT = Control of Allergic Rhinitis and Asthma Test; CARAT-a = CARAT score for asthma; CARAT-r = CARAT score for allergic rhinitis factor; CARAT-t = CARAT total 
score; VAS = Visual Analogue Scale.
TABLE 4 Participants with Uncontrolled Disease According to CARAT Scores and VASa
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FIGURE 2 Score Distribution
A. CARAT-t (n = 224)
B. ACT for AR Subgroup (n = 120)
































ACT = Asthma Control Test; AR = allergic rhinitis only group; CARAT = Control of Allergic Rhinitis and Asthma Test; CARAT-t = CARAT total score.
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medication and self-reported the pathology, we could not con-
firm that AR patients were not in fact ARA patients. Patients 
with AR using OTC medication only were not included, so 
AR may be underreported for prevalence, and control may be 
better than the study shows. Third, even though this study 
encompassed less than 12 months, AR is a seasonal disorder, 
and the occurrence of AR could affect the number of patients 
seeking treatment for it. Our results may also have included 
some patients with chronic obstructive pulmonary disease 
(COPD); however, considering that COPD is highly associated 
with smoking, the results observed were similar for smok-
ers and nonsmokers (Table 3). Considering gender, men may 
have answered questions differently than women, possibly 
downplaying the effects of their disease. In addition, CARAT 
has not yet been validated in the AR only population, although 
some projects testing the CARAT with patients with AR only 
or asthma only are being carried out. Moreover, some patients 
may attribute fatigue to causes other than ARA, which may 
have affected their responses and, thus, some of the results.
■■  Conclusions
This study demonstrated that asthma and AR control are far 
from optimal as measured by the CARAT tool in a community 
pharmacy setting. This study also showed that most patients 
have	a	poor	perception	of	their	disease	control.	Even	with	the	
identified limitations, the results show that patients who suffer 
from ARA may be identified by community pharmacies and 
offered assistance for improved disease control. Assessing ARA 
control at community pharmacies using simple self-assessment 
questionnaires, such as CARAT, may be a first step to change 



























aCorrelations between CARAT and VAS are negative because better control in 
CARAT means worse control in VAS (all P < 0.001).
ACT = Asthma Control Test; CARAT = Control of Allergic Rhinitis and Asthma Test; 
CARAT-a = CARAT score for asthma; CARAT-r = CARAT score for allergic rhinitis 
factor; CARAT-t = CARAT total score; VAS = Visual Analogue Scale.
TABLE 5 Correlations Between 
CARAT, ACT, and VASa
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List of International Common 
Denominations of the Selected 
Medications Used in This Study
Beta-adrenergic Agonists
Quick	action
•	Salbutamol
•	Terbutaline
Long	action
•	Salmeterol
•	Formoterol
Cholinergic Antagonists
•	Ipratropium	bromide
Glucocorticoids
•	Beclomethasone
•	Budesonide
•	Fluticasone
•	Mometasone
•	Betamethasone
Leukotriene Antagonists
•	Montelukast
•	Zafirlukast
Xanthines
•	Aminophylline
•	Theophylline
Cromones
•	Cromoglycic	acid
Antihistamines–Nonsedatives
•	Loratadine
•	Desloratadine
•	Ebastine
•	Fexofenadine
•	Mizolastine
•	Rupatadine
•	Cetirizine
•	Levocetirizine
•	Ketotifen
APPEnDIx
